EGFR and lung carcinoma: Recently, Chen et al. demonstrated that the lncRNA H19 could act via upregulating PKM2 and enhancing Akt phosphorylation to modulate erlotinib resistance in EGFR-mutant lung cancer (Chen C. et al., 2020).